These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
70 related articles for article (PubMed ID: 20222764)
1. Human polymerase alpha inhibitors for skin tumors. Part 2. Modeling, synthesis and influence on normal and transformed keratinocytes of new thymidine and purine derivatives. Höltje M; Richartz A; Zdrazil B; Schwanke A; Dugovic B; Murruzzu C; Reissig HU; Korting HC; Kleuser B; Höltje HD; Schäfer-Korting M J Enzyme Inhib Med Chem; 2010 Apr; 25(2):250-65. PubMed ID: 20222764 [TBL] [Abstract][Full Text] [Related]
2. Innovative agents for actinic keratosis and nanocarriers enhancing skin penetration. Schäfer-Korting M; Höltje M; Korting HC; Höltje HD Skin Pharmacol Physiol; 2010; 23(1):6-14. PubMed ID: 20090403 [TBL] [Abstract][Full Text] [Related]
3. Antitumor effects of guanosine-analog phosphonates identified by molecular modelling. Schwanke A; Murruzzu C; Zdrazil B; Zuhse R; Natek M; Höltje M; Korting HC; Reissig HU; Höltje HD; Schäfer-Korting M Int J Pharm; 2010 Sep; 397(1-2):9-18. PubMed ID: 20600723 [TBL] [Abstract][Full Text] [Related]
4. Molecular modelling studies of new potential human DNA polymerase α inhibitors. Zdrazil B; Schwanke A; Schmitz B; Schäfer-Korting M; Höltje HD J Enzyme Inhib Med Chem; 2011 Apr; 26(2):270-9. PubMed ID: 20958230 [TBL] [Abstract][Full Text] [Related]
5. Topical application of valrubicin has a beneficial effect on developing skin tumors. Andersen SM; Rosada C; Dagnaes-Hansen F; Laugesen IG; de Darkó E; Dam TN; Stenderup K Carcinogenesis; 2010 Aug; 31(8):1483-90. PubMed ID: 20554745 [TBL] [Abstract][Full Text] [Related]
6. An overview of Bcl-2 expression in histopathological variants of basal cell carcinoma, squamous cell carcinoma, actinic keratosis and seborrheic keratosis. Puizina-Ivić N; Sapunar D; Marasović D; Mirić L Coll Antropol; 2008 Oct; 32 Suppl 2():61-5. PubMed ID: 19138009 [TBL] [Abstract][Full Text] [Related]
7. Different pathways are involved in arsenic-trioxide-induced cell proliferation and growth inhibition in human keratinocytes. Bi X; Gu J; Guo Z; Tao S; Wang Y; Tang L; Wu J; Mi Q Skin Pharmacol Physiol; 2010; 23(2):68-78. PubMed ID: 20016248 [TBL] [Abstract][Full Text] [Related]
8. Topical sulindac combined with hydrogen peroxide in the treatment of actinic keratoses. Resnick L; Rabinovitz H; Binninger D; Marchetti M; Weissbach H J Drugs Dermatol; 2009 Jan; 8(1):29-32. PubMed ID: 19180893 [TBL] [Abstract][Full Text] [Related]
9. Cyclooxygenase-2 is a possible target of treatment approach in conjunction with photodynamic therapy for various disorders in skin and oral cavity. Akita Y; Kozaki K; Nakagawa A; Saito T; Ito S; Tamada Y; Fujiwara S; Nishikawa N; Uchida K; Yoshikawa K; Noguchi T; Miyaishi O; Shimozato K; Saga S; Matsumoto Y Br J Dermatol; 2004 Aug; 151(2):472-80. PubMed ID: 15327557 [TBL] [Abstract][Full Text] [Related]
10. Structural basis for inhibition of DNA replication by aphidicolin. Baranovskiy AG; Babayeva ND; Suwa Y; Gu J; Pavlov YI; Tahirov TH Nucleic Acids Res; 2014 Dec; 42(22):14013-21. PubMed ID: 25429975 [TBL] [Abstract][Full Text] [Related]
11. Targeting human DNA polymerase alpha for the inhibition of keratinocyte proliferation. Part 1. Homology model, active site architecture and ligand binding. Richartz A; Höltje M; Brandt B; Schäfer-Korting M; Höltje HD J Enzyme Inhib Med Chem; 2008 Feb; 23(1):94-100. PubMed ID: 18341260 [TBL] [Abstract][Full Text] [Related]
12. The role of apoptosis in therapy and prophylaxis of epithelial tumours by nonsteroidal anti-inflammatory drugs (NSAIDs). Fecker LF; Stockfleth E; Nindl I; Ulrich C; Forschner T; Eberle J Br J Dermatol; 2007 May; 156 Suppl 3():25-33. PubMed ID: 17488403 [TBL] [Abstract][Full Text] [Related]
13. Abnormal expression of retinoic acid receptors and keratin 19 by human oral and epidermal squamous cell carcinoma cell lines. Hu L; Crowe DL; Rheinwald JG; Chambon P; Gudas LJ Cancer Res; 1991 Aug; 51(15):3972-81. PubMed ID: 1713123 [TBL] [Abstract][Full Text] [Related]
14. The erbstatin analogue methyl 2,5-dihydroxycinnamate cross-links proteins and is cytotoxic to normal and neoplastic epithelial cells by a mechanism independent of tyrosine kinase inhibition. Stanwell C; Burke TR; Yuspa SH Cancer Res; 1995 Nov; 55(21):4950-6. PubMed ID: 7585535 [TBL] [Abstract][Full Text] [Related]
15. Emerging drugs for actinic keratosis. Ulrich M; Drecoll U; Stockfleth E Expert Opin Emerg Drugs; 2010 Dec; 15(4):545-55. PubMed ID: 20670178 [TBL] [Abstract][Full Text] [Related]
16. Vitamin D analogs: new therapeutic agents for the treatment of squamous cancer and its associated hypercalcemia. Yu J; Papavasiliou V; Rhim J; Goltzman D; Kremer R Anticancer Drugs; 1995 Feb; 6(1):101-8. PubMed ID: 7756673 [TBL] [Abstract][Full Text] [Related]
17. Analysis of promoter hypermethylation of death-associated protein kinase and p16 tumor suppressor genes in actinic keratoses and squamous cell carcinomas of the skin. Tyler LN; Ai L; Zuo C; Fan CY; Smoller BR Mod Pathol; 2003 Jul; 16(7):660-4. PubMed ID: 12861061 [TBL] [Abstract][Full Text] [Related]
18. Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance. Tantillo C; Ding J; Jacobo-Molina A; Nanni RG; Boyer PL; Hughes SH; Pauwels R; Andries K; Janssen PA; Arnold E J Mol Biol; 1994 Oct; 243(3):369-87. PubMed ID: 7525966 [TBL] [Abstract][Full Text] [Related]
19. Viral DNA detection and RAS mutations in actinic keratosis and nonmelanoma skin cancers. Zaravinos A; Kanellou P; Spandidos DA Br J Dermatol; 2010 Feb; 162(2):325-31. PubMed ID: 19849697 [TBL] [Abstract][Full Text] [Related]
20. The expression of SnoN in normal human skin and cutaneous keratinous neoplasms. Zhang X; Egawa K; Xie Y; Ihn H Int J Dermatol; 2009 Jun; 48(6):579-83. PubMed ID: 19538364 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]